Jean Boulle Medtech Ltd. is active in a wide range
of medical technologies.


Related articles on the Tendyne valve:


If you look closely at the geometric heart in the logo you will see a diamond-shaped octahedron overlay which repeats to create the “flower of life” symbol. The logo combines the elements of diamonds (the Jean Boulle Group’s first initiative), the heart and the tri-leaflet pattern from its first life-saving medical technology project (Tendyne), and the flower of life (symbolizing the focus of Jean Boulle Medtech – saving and improving the quality of people’s lives).


Jean Boulle Medtech ("JBM") founded VDYNE, a medical device company focused on the development of a transcatheter replacement valve to treat patients suffering from tricuspid regurgitation (“TR”). TR occurs when the tricuspid valve is not functioning properly, and thereby fails to close.

The tricuspid valve separates the right atrium from the right ventricle and when the tricuspid valve does not close properly, blood flows backwards from the right ventricle into the right atrium instead of progressing to the heart for re-oxygenation. This "regurgitation" is a debilitating condition that impacts the general health and quality of life of approximately 5% of the elderly population. More importantly, surgical intervention to treat TR has high rates of mortality and morbidity, and there are presently no approved minimally-invasive valve replacement treatment alternatives.

JBM has assembled a strong and highly experienced team at VDYNE team, with a proven track-record in structural heart and the development of transcatheter therapies, including in the adjacent mitral valve replacement space. VDYNE is developing a unique technology with the ability to replace the existing dysfunctional tricuspid valve following delivery of a new prosthetic valve over a catheter (as opposed to open-heart surgery) and thereby reducing mortality rates and the related surgical complications. Importantly, the valve is designed to be completely repositionable and retrievable to enable precise placement by the physician.

VDYNE is currently undertaking late stage pre-clinical testing, including the completion of good laboratory practice compliance and a range of mandatory pre-clinical testing steps. With $6.8m raised in Q4 2019 to fund the continued development of the valve, VDYNE is targeting first-in-man chronic feasibility studies in 2020.


Tendyne Holdings, Inc. developed one of the most promising Transcatheter mitral valve implant (“TMVI”) devices in existence today. The Tendyne TMVI is a fully-retrievable and repositionable, apically-tethered tri-leaflet porcine pericardial valve sewn onto a Nitinol (nickel/titanium composite) frame. It has specifically been designed to address the complex mitral anatomy of functional, degenerative and mixed aetiology mitral regurgitation. When left untreated, mitral regurgitation can lead to heart failure and death. When implanted in a beating heart, the Tendyne valve has proprietary and patented features that permit a significantly less invasive procedure to mitral valve treatment than open-heart surgery. This life-saving device currently is in worldwide clinical trials in the United States, the United Kingdom, and Australia at renowned hospitals such as Baylor’s Hamilton Heart and Vascular Hospital in Dallas, Texas; the Minneapolis Heart Institute and Abbott Northwestern Hospital in Minneapolis Minnesota; the Royal Brompton Hospital in London, England; and St. Vincent’s Hospital, Sydney Australia, among others. Tendyne and the hospitals are reporting positive outcomes. Jean Boulle Medtech was the founding investor of Tendyne and helped guide the company through its many stages of development. In 2012 and 2014 respectively, Jean Boulle Medtech welcomed Abbott Laboratories and Apple Tree Partners as Tendyne’s other major investors. Abbott acquired Tendyne in September 2015. The Tendyne valve is currently undergoing large-scale human trials for CE Mark and FDA approval.

For more information, see

Related videos on the Tendyne valve:


Jean Boulle Medtech is the anchor founding investor in NanoPhagix LLC, which is developing a patented nanoparticle drug treatment for atherosclerosis. The drug is designed to directly target rupture-prone plaques inside the vessel walls of the human circulatory system to reduce vessel inflammation. That should in turn reduce the narrowing of the vessel and the risk of plaque cap rupture, either or both of which events can result in blood clots, heart attack, stroke or other organ damage. The drug is currently undergoing animal trials.

Confidentiality and protection of proprietary technologies limit the information that can currently be provided, but more information will be made available as soon as circumstances permit it. Jean Boulle Medtech welcomes enquiries from those seeking financial and technical expertise to develop technologies that saves lives or improves the quality of life.

25B Boulevard Royal
L2449 Luxembourg
Grand Duchy Luxembourg

Tel: +352 222 512
Fax: +352 222 413

The Jean Boulle Group acquires promising assets and projects, then optimizes their structure, management and development with private and public investment.

The Jean Boulle Group has been a member of the US Corporate Council on Africa since the Council’s inception.


Something went wrong. Please check your entries and try again.

Copyright © 2019 Jean Boulle Group. All rights reserved.